» Articles » PMID: 21838519

The Utilization and Outcome of Diagnostic, Predictive, and Prenatal Genetic Testing for Huntington Disease in Johannesburg, South Africa

Overview
Date 2011 Aug 16
PMID 21838519
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Huntington disease (HD) is an autosomal dominant neurodegenerative disorder for which genetic counseling and testing are available in South Africa.

Objective: The purpose of this study was to assess the utilization of the services available in Johannesburg for diagnostic, predictive, and prenatal genetic testing and counseling for HD and the characteristics of the patients who use them.

Subjects And Methods: A retrospective study was conducted using records of patients (n=287) who had genetic counseling and/or testing for HD through the Division of Human Genetics, National Health Laboratory Service and University of the Witwatersrand, Johannesburg, between January 1998 and December 2006. Age, gender, number of children, ethnicity, and test results were analyzed.

Results: Of the 287 patients included in this study, 77% had diagnostic testing, 20% predictive, and 3% prenatal testing. In the diagnostic group, 47% of subjects tested positive for HD1 and 9% for HDL2 (all Black or of mixed ancestry). Altogether, 66.7% of subjects in the predictive group had testing and 39.5% were positive. In both groups, White subjects were overrepresented. In seven prenatal tests, three fetuses (including a set of twins) tested positive for HD and termination of pregnancy was requested.

Discussion And Conclusion: The HD services for predictive and prenatal testing appear to be underutilized, especially by Black individuals, possibly because of lack of awareness among these individuals and among healthcare providers and/or a lower HD prevalence in this group. Recognition of and testing for HDL2 is important in South Africa's large Black population, and HD testing services cannot be considered complete unless testing for both HD1 and HDL2 are undertaken.

Citing Articles

The Changing Age of Individuals Seeking Presymptomatic Genetic Testing for Huntington Disease.

Holman M, Quillin J, York T, Testa C, Rosen A, Norris V J Genet Couns. 2018; 27(5):1157-1166.

PMID: 29460111 DOI: 10.1007/s10897-018-0233-9.


1993-2014: two decades of predictive testing for Huntington's disease at the Medical Genetics Unit of the University of Genoa.

Mandich P, Lamp M, Gotta F, Gulli R, Iacometti A, Marchese R Mol Genet Genomic Med. 2017; 5(5):473-480.

PMID: 28944231 PMC: 5606876. DOI: 10.1002/mgg3.238.


Progressive and self-limiting neurodegenerative disorders in Africa: a new prominent field of research led by South Africa but without strong health policy.

Poreau B Pan Afr Med J. 2016; 23:220.

PMID: 27872676 PMC: 5111969. DOI: 10.11604/pamj.2016.23.220.8475.


Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at-risk observational study (PHAROS).

Quaid K, Eberly S, Kayson-Rubin E, Oakes D, Shoulson I Clin Genet. 2016; 91(6):824-831.

PMID: 27740685 PMC: 5392180. DOI: 10.1111/cge.12893.


Prenatal testing in Huntington disease: after the test, choices recommence.

Bouchghoul H, Clement S, Vauthier D, Cazeneuve C, Noel S, Dommergues M Eur J Hum Genet. 2016; 24(11):1535-1540.

PMID: 27302844 PMC: 5110058. DOI: 10.1038/ejhg.2016.59.